CEO, Anders Månsson will be at the Nordic Life Science Days in Copenhagen

CEO, Anders Månsson and CFO, Tore Kvam will present Oncoinvent to investors during the JP Morgan 42nd Annual Healthcare Conference

CEO, Anders Månsson will present Oncoinvent at the DNB Nordic Healthcare Conference 2023

Oncoinvent will be presenting the company at the Nordic American Healthcare Conference 2023. The company will be represented by CEO Anders Månsson and CFO Tore Kvam

Progressing to study Radspherin® in the first-line treatment setting for ovarian cancer

IND clearance is now obtained for both lead indications for Radspherin®

This marks the first IND clearance for initiation of Radspherin® clinical trials in the US

Oncoinvent would like to extend an invitation to a short update on the company and a presentation on Q3 report including outlook. The presentation will be held on Thursday 23. November 2023 at 10:00 AM in the offices of Carnegie, Fjordalléen 16, Oslo, 5. floor, Meeting room: Verftet. It will also be possible to attend … Read more

CEO, Anders Månsson and CFO, Tore Kvam presented Oncoinvent at the Radforsk’s podcast Radium episode 284. The podcast can be heard HERE (norwegian)  

CEO, Anders Månsson presentes Oncoinvent at the LSX conference and meet with investors.

At 18 months, no patients at the recommended dose of 7 MBq experienced peritoneal recurrences

Robust safety profile demonstrated, no serious adverse events related to Radspherin® reported
Presentation on October 4, 2023, at 11:55 a.m. CET (5:55 a.m. EDT)

Anders Månsson

Chief Executive Officer

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.